Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | INA03 |
| Synonyms | |
| Therapy Description |
INA03 is an antibody-drug conjugate (ADC) targeting TFRC (CD71), which potentially induces tumor cell death and decreases tumor growth (PMID: 38641421). |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| INA03 | INA-03|INA 03 | INA03 is an antibody-drug conjugate (ADC) targeting TFRC (CD71), which potentially induces tumor cell death and decreases tumor growth (PMID: 38641421). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT03957915 | Phase I | INA03 | Study of Escalating Doses of INA03 Administered Intravenously as Single Agent in Adult Patients With Relapse/Refractory Acute Leukemia (INA03) | Completed | FRA | 0 |